Inoviv: Funding Raised To Expand Quantitative Proteomics Product Offerings
Summary
Biomarker company Inoviv announced it has secured significant funding from venture capital firm Hoxton Ventures and leading investment manager Foresight Group to expand the delivery of highly accurate, fully quantitative targeted biomarker workflows and panels.Building on a previous funding round from Hoxton Ventures, this latest investment will enable Inoviv to expand its commercial activities further to support the pharmaceutical and biotech space in support of clinical proteomics, including clinical trial monitoring while also extending R&D capacity and innovation to address the fast-growing biomarker market and accelerate the development and approval of life-changing therapeutics.Inoviv offers bespoke and off-the-shelf multiplexed, fully quantitative, and validated assays. Assays could be tailored according to the drug, disease, and mechanism of action, and are carried out in GLP/GCP accredited laboratories.We are delighted to announce this investment from Hoxton Ventures and Foresight Group. There has never been a more pressing need for technologies that can deliver definitive, fully quantitative data to accelerate clinical development and regulatory approval. This funding represents a significant milestone in Inovivs journey and will allow us to grow the capacity we need to deliver on the promise of precision biomarkers for the global pharmaceutical research community.Inoviv has pioneered a groundbreaking technology platform rooted in targeted proteomics, poised to revolutionize the landscape of biomarker test development for pharmaceutical companies. We look forward to seeing the increasing momentum behind Inovivs technology and its growing applications in support of drug development and clinical trials.